China adds JW Therapeutics’ CAR-T drug to national insurance, price cut to under 300,000 yuan

The roughly fourfold reduction from the pre-listing price is the headline number, but the more consequential signal is that a CAR-T therapy has cleared China's national reimbursement process at all, which sets a reference point for how the country's payer intends to treat high-cost cell therapies. The direct beneficiaries are eligible patients and JW Therapeutics, whose volume economics now shift from a small self-pay market to a reimbursed one. Whether the negotiated price leaves room for sustainable manufacturing and whether other CAR-T developers pursue the same route is the open question worth watching.